Form 4: Werewolf Therapeutics Director Morrison Briggs Granted 27,000 Stock Options

Werewolf Therapeutics, Inc. Director Morrison Briggs was granted 27,000 stock options with an exercise price of $1.29, vesting on the earlier of the first anniversary of the grant date or the next annual meeting.

Summary

• Morrison Briggs, a Director of Werewolf Therapeutics, Inc. (HOWL), was granted 27,000 stock options.
• The options have an exercise price of $1.29 per share.
• The grant date for these options was June 12, 2025.
• The options vest in full on the earlier of June 12, 2026 (the first anniversary of the grant date) or the next annual meeting of stockholders following the grant date, subject to Mr. Briggs' continued service as a director.
• The options are set to expire on June 11, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard practice for aligning interests and incentivizing long-term performance, which is generally viewed positively as it links the director's financial success to the company's stock performance.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance and value creation for Werewolf Therapeutics, Inc.

Future Outlook

This document is a disclosure of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a director, a common practice across industries, including biotechnology, to align executive and board member incentives with shareholder value. It does not provide broader industry trend insights.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice, aligning with typical corporate governance structures aimed at incentivizing long-term performance and retention. The specific terms (exercise price, vesting schedule) would need comparison to peer companies in the biotechnology or pharmaceutical sector to assess their competitiveness, but such details are not provided in this filing.

Related Party Transactions

• Grant of 27,000 stock options to Morrison Briggs, a Director of Werewolf Therapeutics, Inc., as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also improved alignment of the director's interests with shareholder value.
• Director (Morrison Briggs): Receives equity compensation, providing a direct financial incentive tied to the company's stock performance and long-term success.

Next Steps

• Continued service of Morrison Briggs as a director for the options to vest.
• The next annual meeting of stockholders, which is a potential vesting trigger for the options.
• Potential exercise of the options by Morrison Briggs at or after the vesting date and before the expiration date.

Key Dates

Keywords

Werewolf Therapeutics, HOWL, Stock Option, Director, SEC Form 4, Insider Transaction, Equity Grant, Executive Compensation